Paroxetine in Brief
- Active ingredient: Paroxetine hydrochloride
- Common brand names: Paxil, Paxil CR, Seroxat, Aropax,
Pondera, Deroxat, Paroxat, Cebrilin
- Drug class: Antidepressant, Selective serotonin
reuptake inhibitor (SSRI)
- FDA Approved: December 29, 1992
- Chemical Formula: C19H20FNO3
- Pregnancy Category: D
- Habit forming? No
- Originally discovered: 1975, Ferrosan, Denmark
Paroxetine was first developed in 1975 by Jorgen Buus-Lassen
and colleagues working in a small Danish company called Ferrosan. Paroxetine
was Buus-Lassen’s the second SSRI. In 1975, this group had produced
femoxetine, which was in clinical trials by the time paroxetine came
along. Femoxetine had a disadvantage compared to paroxetine - it needed
high doses, between 300 and 600 mg. It was not going to be a simple
once-a-day pill. But in clinical trials femoxetine appeared more effective
Ferrosan patented the formula for the paroxetine in February 8th, 1977
under U.S. Patent #4,007,196. The patent claims paroxetine and its salts
and discloses their antidepressant properties. Ferrosan eventually developed
a process to produce the crystalline hydrochloride salt of paroxetine,
or paroxetine hydrochloride.
Ferrosan sold paroxetine to Beecham pharmaceuticals in 1980. Beecham
later merged with SmithKline & French to become SmithKline Beecham (SB)
and later at the turn of the millennium with Glaxo to become GlaxoSmithKline
(GSK), at that point the world’s largest pharmaceutical corporation.
Ferrosan had meanwhile been acquired by Novo-Nordisk, which had little
interest in psychiatry, and femoxetine died from neglect.
Paroxetine ended up being licensed as Paxil in 1993 in the United States
and Seroxat in 1992 in the United Kingdom. As part of the effort to
make up ground on the others, marketers within SmithKline Beecham coined
the acronym SSRI. Compared to the other serotonin reuptake inhibitors,
paroxetine was supposedly the selective serotonin reuptake inhibitor
- the SSRI. The name worked - too well. It was adopted for the entire
group of compounds. In this way, Paxil made Prozac and Zoloft into SSRIs.
FDA approved indications
- Major depressive disorder
- Obsessive compulsive disorder
- Panic disorder
- Social anxiety disorder
- Generalized anxiety disorder
- Posttraumatic stress disorder
- Premenstrual dysphoric disorder (controlled release formulation)
Off-label & Investigational uses
- chronic tension-type headache 12
- chronic daily headache 13
- fibromyalgia 19
- hot flashes 14
- premature ejaculation 15, 16
- bipolar disorder 17
- diabetic neuropathy 18
- compulsive gambling 20
- irritable bowel syndrome (IBS) 21,
- social anxiety disorder in in children and adolescents
Paroxetine is an effective therapy for premature ejaculation. Paroxetine
20 mg daily and scheme on-demand (20 mg 4-6 hours before the intercourse)
appears similar like effective options 15,
Irritable Bowel Syndrome (IBS)
Antidepressants are recommended for severe or refractory symptoms of
pain, and may be helpful for other symptoms like constipation. Paroxetine
has neuromodulatory and analgesic properties independent of its psychotropic
effect, which may set in relatively fast.
The clinical study found that patients taking 10 to 40 mg of paroxetine
per day were more likely than those taking placebo to have a
clinically significant improvement in overall well-being (63% versus
26%). This benefit was present in both depressed and non-depressed patients
A pilot open-label study suggested that paroxetine 20 to 40 mg is effective
in reducing pain and other IBS symptoms (constipation and diarrhea)
Paroxetine "pros" and "cons"
Paroxetine (Paxil) may be useful antidepressant in patients with anxiety
disorder or insomnia. It should probably be avoided in
persons for whom the mild anticholinergic effects would be undesirable,
such as those with Alzheimer's disease or other cognitive disorders.
- broad therapeutic efficacy
- inhibits fewer CYP enzymes than fluoxetine
- the only SSRI indicated for all five anxiety disorders in addition
to major depressive disorder
- long-term treatment efficacy and tolerability 8
- highest incidence rate and severity of SSRI withdrawal syndrome
- high risk for weight gain 3
(weight gain related to paroxetine occurs mainly during
the first 12 months of treatment)
- high rate of sexual side effects (up to 75%), produces a significant
delay in male ejaculation, significantly decreases libido, arousal,
and duration of orgasm
- high rate of drowsiness and sedation, higher than with fluoxetine,
sertraline and venlafaxine
- may impair cognition and vigilance
Mechanism of action
Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor
of the reuptake of serotonin of all currently available antidepressants
including the class of SSRIs. It is a very weak inhibitor of norepinephrine
(NE) uptake but it is still more potent at this site than the other
SSRIs. In vitro, paroxetine is approximately 3- to 5-fold more potent
at inhibiting serotonin than noradrenaline reuptake.
Paroxetine has little affinity for muscarinic cholinergic, histamine
H1, dopaminergic and adrenergic receptors and by comparison with tricyclic
antidepressants (TCAs) has, therefore, reduced propensity to cause central
and autonomic side effects. Paroxetine is also a nitric oxide synthase
(NOS) inhibitor, hence serum nitrite and nitrate levels are reduced
in paroxetine users.
Paroxetine potently and selectively inhibits neuronal serotonin reuptake
through antagonism of the serotonin transporter. Its antidepressant,
antiobsessional, and antipanic activities are presumed to be linked
to potentiation of serotonergic activity in the central nervous system
(CNS). Paroxetine inhibits the active membrane transport mechanism for
reuptake of serotonin, which increases concentration of the neurotransmitter
at the synaptic cleft and prolongs its activity at synaptic receptor
sites. Inhibition of serotonin reuptake also enhances serotonergic neurotransmission
by reducing turnover of the neurotransmitter via a negative feedback
mechanism. Paroxetine inhibits serotonin reuptake in vitro more selectively
and more potently than do fluoxetine, sertraline, fluvoxamine, zimeldine,
Time to clear out of the system
The elimination half-life is variable but is generally about 21 hours
(3-65 hours). Paroxetine has no active metabolites. Half-life is prolonged
in patients with severe hepatic or renal function impairment. Generally, it is more rapidly cleared in youths than adults.
It may take 5 to 12 days for paroxetine to clear out of the system.
Onset of action
Depression: Studies have shown, that depressive and anxiety
symptoms may improve after 1 week with paroxetine 9.
However, it may take up to 6 weeks for the full therapeutic effect to
Generalized anxiety disorder: In generalized anxiety disorder
(GAD) improvement of core symptoms occurs early after 1 week and significant
reduction in disability occurs after only 8 weeks of treatment 10.
Posttraumatic stress disorder: It may take up to 12 weeks to
achieve significant reduction of PTSD symptoms 11.
Paroxetine (Paxil) withdrawal
Withdrawal problems occur more commonly and are more severe with paroxetine
than with the other SSRIs. The risk of withdrawal symptoms depends on
several factors including the duration and dose of therapy and the rate
of dose reduction.
Discontinuation symptoms include:
- sensory disturbances (including paraesthesia, electric shock sensations
- sleep disturbances (including intense dreams)
- emotional instability
- visual disturbances
In order to minimise the chance of withdrawal problems, it is suggested
that paroxetine should be withdrawn very gradually by reducing the dose
very slowly over a period of weeks, or months in cases where the symptoms
By reducing the dosage in small increments, your serotonergic system
can gradually take over it's own natural serotonin producing activity
and slowly adapt to living without the drug. The tapering process may
consist of gradual dose reduction of 5% per week.
The taper phase regimen used in clinical trials involved decreasing
the daily dose by 10 mg at weekly intervals. However, such regimen may
be too fast. If intolerable symptoms occur following a decrease in the
dose, then resuming the previous dose may be considered. When symptoms
have settled, resume tapering process at a more gradual rate.
Paroxetine & alcohol
Paroxetine does not impair psychomotor function and does not potentiate the
depressant effects of ethanol.
- 1. U.S. FDA. Paroxetine
- 2. Hindmarch I, Kimber S, Cockle SM. Abrupt and
brief discontinuation of antidepressant treatment: effects on cognitive
function and psychomotor performance. Int Clin Psychopharmacol. 2000
- 3. Fava M, Judge R, Hoog SL, Nilsson ME, Koke
SC. Fluoxetine versus sertraline and paroxetine in major depressive
disorder: changes in weight with long-term treatment. J Clin Psychiatry.
2000 Nov;61(11):863-7. PubMed
- 4. Alison Tonks. Withdrawal from paroxetine can
be severe, warns FDA. BMJ. 2002 February 2; 324(7332): 260.
- 5. Montejo-Gonzalez AL, Llorca G, Izquierdo
JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel
E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin
T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction. J Sex
Marital Ther. 1997 Fall;23(3):176-94. PubMed
- 6. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition
of norepinephrine uptake in patients with major depression treated
with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10.
- 7. Wagner KD, Berard R, Stein MB, Wetherhold
E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A. A multicenter,
randomized, double-blind, placebo-controlled trial of paroxetine in
children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004 Nov;61(11):1153-62.
- 8. Rickels K, Rynn M, Iyengar M, Duff D. Remission
of generalized anxiety disorder: a review of the paroxetine clinical
trials database. J Clin Psychiatry. 2006 Jan;67(1):41-7.
- 9. Golden RN, Nemeroff CB, McSorley P, Pitts
CD, Dube' EM. Efficacy and tolerability of controlled-release and
immediate-release paroxetine in the treatment of depression. J Clin
Psychiatry. 2002 Jul;63(7):577-84. PubMed
- 10. Pollack MH, Zaninelli R, Goddard A, McCafferty
JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment
of generalized anxiety disorder: results of a placebo-controlled trial. J Clin Psychiatry. 2001 May;62(5):350-7. PubMed
- 11. Tucker P, Zaninelli R, Yehuda R, Ruggiero
L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic
posttraumatic stress disorder: results of a placebo-controlled
trial. J Clin Psychiatry. 2001 Nov;62(11):860-8. PubMed
- 12. Holroyd KA, Labus JS, O'Donnell FJ, Cordingley
GE. Treating chronic tension-type headache not responding to amitriptyline
hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache.
2003 Oct;43(9):999-1004. PubMed
- 13. Foster CA, Bafaloukos J. Paroxetine in the
treatment of chronic daily headache. Headache. 1994 Nov-Dec;34(10):587-9.
- 14. Stearns V, Beebe KL, Iyengar M, Dube E.
Paroxetine controlled release in the treatment of menopausal hot flashes:
a randomized controlled trial. JAMA. 2003 Jun 4;289(21):2827-34.
- 15. Ludovico GM, Corvasce A, Pagliarulo G, Cirillo-Marucco
E, Marano A, Pagliarulo A. Paroxetine in the treatment of premature
ejaculation. Br J Urol. 1996 Jun;77(6):881-2. PubMed
- 16. Rivera P, Gonzalez R, Gonzalez F, Storme
O. Use of paroxetine on-demand in premature ejaculation. Actas Urol
Esp. 2005 Apr;29(4):387-91. PubMed
- 17. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004 Dec;65(12):1715-9. PubMed
- 18. Sindrup SH, Gram LF, Brosen K, Eshoj O,
Mogensen EF. The selective serotonin reuptake inhibitor paroxetine
is effective in the treatment of diabetic neuropathy symptoms. Pain.
1990 Aug;42(2):135-44. PubMed
- 19. Patkar AA, Masand PS, Krulewicz S, Mannelli
P, Peindl K, Beebe KL, Jiang W. A randomized, controlled, trial of
controlled release paroxetine in fibromyalgia. Am J Med. 2007 May;120(5):448-54.
- 20. Grant JE, Kim SW, Potenza MN, Blanco C,
Ibanez A, Stevens L, Hektner JM, Zaninelli R. Paroxetine treatment
of pathological gambling: a multi-centre randomized controlled trial.
Int Clin Psychopharmacol. 2003 Jul;18(4):243-9. PubMed
- 21. Masand PS, Gupta S, Schwartz TL, Virk S,
Lockwood K, Hameed A, King M, Kaplan DS. Paroxetine in Patients With
Irritable Bowel Syndrome: A Pilot Open-Label Study. Prim Care Companion
J Clin Psychiatry. 2002 Feb;4(1):12-16. PubMed
- 22. Tabas G, Beaves M, Wang J, Friday P, Mardini
H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled
trial. Am J
Gastroenterol. 2004 May;99(5):914-20.
- 23. Lepkifker E, Dannon PN, Ziv R, Iancu I,
Horesh N, Kotler M. The treatment of kleptomania with serotonin reuptake
inhibitors. Clin Neuropharmacol. 1999 Jan-Feb;22(1):40-3.
Published: March 31, 2008
Last updated: April 12, 2012
- Paroxetine inhibits its own metabolism.
The starting dose of paroxetine has an elimination half-life of
approximately 24 h. However, the half-life becomes longer at higher doses due to paroxetine's inhibition of its own
- Paroxetine is the most potent inhibitor of the reuptake of serotonin
among the available SSRIs.
- Paroxetine, currently classified as a selective serotonin reuptake
inhibitor, can act as a serotonin and norepinephrine uptake inhibitor
in vivo 6.